A patented, synthetic CBD to address pain and addiction

SUPERA-1R is a synthetic, preclinical cannabidiol derivative that targets CB2 receptors.


SUPERA-1R is non-toxic and approximately 7-8X more effective than plant-derived CBD in reducing MAO-A and MAO-B, which play a role in substance addiction, in a dose-dependent manner.


Supera-1R is being developed to address anxiety, chronic pain, and seizures and is expected to begin human trials as a therapy for epilepsy, followed by chronic pain.


Supera-1R binds to and inhibits opioid receptors, comparing it side by side with plant-based CBD. Opioid receptors are G protein-coupled receptors, widely expressed in the brain, spinal cord, peripheral neurons, and digestive tract.

Pre-clinical studies

Supera-1R is a novel synthetic molecule with stark functional and structural similarity to cannabidiol (CBD).

In studies with scientific collaborators, Supera-1R has demonstrated antidepressant and anti-anxiety effects with much higher potency and efficacy than plant-derived CBD.  CBD has broad therapeutic properties across a range of neuropsychiatric disorders, but without the psychoactive effects of THC.


Addressing an unmet need for pharmaceutical cannabinoids

Building on CBD’s enormous pre-existing market acceptance and the FDA’s declared receptiveness to moving forward in this space, SUPERA-1R is positioned to become a prescription drug alternative to unregulated CBD.

View MyMD Thought Leadership and News
  • This field is for validation purposes and should be left unchanged.